Showing 3881-3890 of 5773 results for "".
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Quantel Medical Launches C.STIM, a New Generation IPL System for Dry Eyehttps://modernod.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/Quantel Medical announced the launch of C.STIM IPL system. Based on intense pulsed light technology, C.STIM is the new generation of IPL designed to treat the root causes of dry eyes: meibomian gland dysfunction, inflammation, and demodex. “Thanks to the unique
- Lumenis Partners With Mandy Moore to Raise Awareness of Dry Eye Disease and OptiLight Treatmenthttps://modernod.com/news/lumenis-partners-with-mandy-moore-partners-to-raise-awareness-of-dry-eye-disease-and-optilight-treatment/2480624/Lumenis announced that it has partnered with singer-songwriter and actress Mandy Moore as a brand ambassador for OptiLight, a solution for dry eyes. Ms. Moore suffered from dry eye disease and treatment with OptiLight significantly improved her condition. She
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmissionhttps://modernod.com/news/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission/2480621/Eyenovia announced that the company successfully completed a meeting with the FDA related to the refiling of the NDA for MydCombi. On October 22, 2021, Eyenovia received a complete response letter (CRL) from the FDA stating that MydCombi, the co
- My Vision Show 2022 to Preview "The Optiverse"https://modernod.com/news/my-vision-show-2022-to-preview-the-optiverse/2480615/My Vision Show, an optical virtual events production and media company, announced that My Vision Show Spring 2022,
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Modelhttps://modernod.com/news/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/2480611/Skye Bioscience announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining greater function of the eye’s retinal ganglion cells (RGCs) versus vehicle control. RGCs are cells